Biologics CDMO with integrated cell line, process, and GMP manufacturing
Avid Bioservices operates a vertically integrated biologics contract development and manufacturing organization (CDMO), running a full-stack platform from cell line development through commercial GMP production. The hiring profile—dominated by manufacturing roles with a notable spike in mid-level and senior positions—reflects a company scaling production capacity rather than product innovation; simultaneously, active projects centered on tech transfer, downstream purification, and CHO cell line optimization suggest operational focus on reliability and cost control as core competitive levers.
Notable leadership hires: Director of Engineering
Avid Bioservices is a public CDMO supporting biotech and pharma companies through the full development lifecycle. The company operates U.S.-based facilities and offers integrated capabilities in cell line development, process development, and CGMP manufacturing for monoclonal antibodies, biosimilars, recombinant proteins, and enzymes. Its technology platforms are designed to reduce risk during scale-up and tech transfer, with emphasis on predictable timelines, regulatory compliance, and operational consistency from early-phase through commercial supply.
Avid is a biologics CDMO offering integrated cell line development, process development, and GMP manufacturing services for monoclonal antibodies, biosimilars, recombinant proteins, and enzymes, operating across the full development lifecycle.
Avid is headquartered in Tustin, California, with U.S.-based manufacturing facilities supporting clinical and commercial-scale biologics production.
Avid Bioservices's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.